MC
BMRN icon

Maverick Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Maverick Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,833
Closed -$451K – 357
2021
Q3 		$451K Sell
5,833
-647
-10% -$51K ﹤0.01% 449
2021
Q2 		$541K Buy
+6,480
New +$514K 0.01% 377

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Maverick Capital's BMRN Position: Q4 2021 in Review

Maverick Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2021, closing a stake of 5,833 shares — an estimated $451K sold.

Maverick Capital first reported a position in BMRN in Q2 2021 and held it in 2 quarters. The position peaked at $541K in Q2 2021. 556 funds tracked by Wall St. Rank hold BMRN as of Q4 2021.

  • Maverick Capital reported no remaining BioMarin Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Maverick Capital sold 5,833 BioMarin Pharmaceuticals shares in Q4 2021, an estimated $451K.
  • Maverick Capital first reported a position in BioMarin Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Maverick Capital's BioMarin Pharmaceuticals position peaked at $541K in Q2 2021.
  • 556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2021.

Based on Maverick Capital's 13F filing for Q4 2021, filed 14 Feb 2022.